Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Co-authors
(698)
Frank V. Fossella
21
Amir Onn
21
Ralph G. Zinner
19
Waun Ki Hong
17
Bonnie S. Glisson
16
Journals
(49)
Lung Cancer
31
J CLIN ONCOL
24
CLIN LUNG CANCER
19
EJC SUPPL
12
J THORAC ONCOL
12
Keywords
(246)
Embed
Subscribe
Academic
Authors
Roy S. Herbst
Roy S. Herbst,University of Texas M.D. Anderson Cancer Center,Oncology,Pharmacology,Neuroscience
Edit
Roy S. Herbst
University of Texas M.D. Anderson Cancer Center
Publications:
212
|
Citations:
4941
Fields:
Oncology
,
Pharmacology
,
Neuroscience
View FAQ about top research areas and Fields of study
Collaborated with
698 co-authors
from 1989 to 2011
|
Cited by
13224 authors
Cumulative
Annual
Sort by:
Publications
(212)
BibTeX
|
RIS
|
RefWorks
Download
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
(
Citations: 1
)
Roy S Herbst
,
Rafat Ansari
,
Frederique Bustin
,
Patrick Flynn
,
Lowell Hart
,
Gregory A Otterson
,
Gordana Vlahovic
,
Chang-Heok Soh
,
Paula O'Connor
,
John Hainsworth
Journal:
Lancet
, vol. 377, no. 9780, pp. 1846-1854, 2011
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
(
Citations: 1
)
Hai T. Tran
,
Ralph G. Zinner
,
George R. Blumenschein Jr
,
Yun W. Oh
,
Vassiliki A. Papadimitrakopoulou
,
Edward S. Kim
,
Charles Lu
,
Mubashira Malik
,
Bert L. Lum
,
Roy S. Herbst
Journal:
Investigational New Drugs - INVEST NEW DRUG
, vol. 29, no. 3, pp. 499-505, 2011
Methodological and practical challenges for personalized cancer therapies
Ignacio I. Wistuba
,
Juri G. Gelovani
,
Jörg J. Jacoby
,
Suzanne E. Davis
,
Roy S. Herbst
Journal:
Nature Reviews Clinical Oncology - NAT REV CLIN ONCOL
, vol. 8, no. 3, pp. 135-141, 2011
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
(
Citations: 20
)
Roy S Herbst
,
Yan Sun
,
Wilfried EE Eberhardt
,
Paul Germonpré
,
Nagahiro Saijo
,
Caicun Zhou
,
Jie Wang
,
Longyun Li
,
Fairooz Kabbinavar
,
Yukito Ichinose
,
Shukui Qin
,
Li Zhang
http://academic.research.microsoft.com/io.ashx?type=5&id=32110613&selfId1=50393387&selfId2=0&maxNumber=12&query=
Journal:
Lancet Oncology - LANCET ONCOL
, vol. 11, no. 7, pp. 619-626, 2010
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
(
Citations: 12
)
R. S. Herbst
,
S. G. Eckhardt
,
R. Kurzrock
,
S. Ebbinghaus
,
P. J. O'Dwyer
,
M. S. Gordon
,
W. Novotny
,
M. A. Goldwasser
,
T. M. Tohnya
,
B. L. Lum
,
A. Ashkenazi
,
A. M. Jubb
http://academic.research.microsoft.com/io.ashx?type=5&id=30841702&selfId1=50393387&selfId2=0&maxNumber=12&query=
Journal:
Journal of Clinical Oncology - J CLIN ONCOL
, vol. 28, no. 17, pp. 2839-2846, 2010
Sort by:
Citations
(4941 times by 3470 publications)
Molecular pathology of lung cancer: key to personalized medicine
(
Citations: 1
)
Liang Cheng
,
Riley E Alexander
,
Gregory T MacLennan
,
Oscar W Cummings
,
Rodolfo Montironi
,
Antonio Lopez-Beltran
,
Harvey M Cramer
,
Darrell D Davidson
,
Shaobo Zhang
Journal:
Modern Pathology - MODERN PATHOL
, vol. 25, no. 3, pp. 347-369, 2012
Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer
Satoshi Inoue
,
Rameshwar Patil
,
Jose Portilla-Arias
,
Hui Ding
,
Bindu Konda
,
Andres Espinoza
,
Dmitriy Mongayt
,
Janet L. Markman
,
Adam Elramsisy
,
H. Westley Phillips
,
Keith L. Black
,
Eggehard Holler
http://academic.research.microsoft.com/io.ashx?type=5&id=57402676&selfId1=50393387&selfId2=0&maxNumber=12&query=
Journal:
PLOS One
, vol. 7, no. 2, 2012
Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Ming Li
,
Qian Zhang
,
Peifang Fu
,
Ping Li
,
Aimei Peng
,
Guoliang Zhang
,
Xiaolian Song
,
Min Tan
,
Xuan Li
,
Yang Liu
,
Yueping Wu
,
Suyun Fan
http://academic.research.microsoft.com/io.ashx?type=5&id=57404733&selfId1=50393387&selfId2=0&maxNumber=12&query=
Journal:
PLOS One
, vol. 7, no. 5, 2012
Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis
T Smirnova
,
Z N Zhou
,
R J Flinn
,
J Wyckoff
,
P J Boimel
,
M Pozzuto
,
S J Coniglio
,
J M Backer
,
A R Bresnick
,
J S Condeelis
,
N E Hynes
,
J E Segall
Journal:
Oncogene
, vol. 31, no. 6, pp. 706-715, 2012
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation
Matthew D. Wilkerson
,
Xiaoying Yin
,
Vonn Walter
,
Ni Zhao
,
Christopher R. Cabanski
,
Michele C. Hayward
,
C. Ryan Miller
,
Mark A. Socinski
,
Alden M. Parsons
,
Leigh B. Thorne
,
Benjamin E. Haithcock
,
Nirmal K. Veeramachaneni
http://academic.research.microsoft.com/io.ashx?type=5&id=57404501&selfId1=50393387&selfId2=0&maxNumber=12&query=
Journal:
PLOS One
, vol. 7, no. 5, 2012
Comments